KR101352588B1 - 당뇨병 치료용 디펩티딜 펩티다아제 억제제 - Google Patents
당뇨병 치료용 디펩티딜 펩티다아제 억제제 Download PDFInfo
- Publication number
- KR101352588B1 KR101352588B1 KR1020087007906A KR20087007906A KR101352588B1 KR 101352588 B1 KR101352588 B1 KR 101352588B1 KR 1020087007906 A KR1020087007906 A KR 1020087007906A KR 20087007906 A KR20087007906 A KR 20087007906A KR 101352588 B1 KR101352588 B1 KR 101352588B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- composition
- delete delete
- antidiabetic
- methyl
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/04—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines without replacement of the other oxygen atom of the carboxyl group, e.g. imino-ethers
- C07C257/06—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines without replacement of the other oxygen atom of the carboxyl group, e.g. imino-ethers having carbon atoms of imino-carboxyl groups bound to hydrogen atoms, to acyclic carbon atoms, or to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
- C07C317/40—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Description
군 |
당화 헤모글로빈 (%) |
군 A (대조군) |
6.2 ± 0.4 |
군 B (화합물 Ⅰ) |
5.8 ± 0.5 |
군 C (피오글리타존) |
5.0 ± 0.7 |
군 D (화합물 Ⅰ + 피오글리타존 |
4.1 ± 0.6 |
군 |
혈장 글루코오스 (㎎/dL) |
군 A (대조군) |
398.7 ± 10.5 |
군 D (화합물 Ⅰ + 보글리보오스) |
153.5 ± 18.5 |
Claims (97)
- 제1항에 있어서, 상기 단일 투여 제형은 화합물 I을 10 mg 내지 200 mg 함유하는 것인 조성물.
- 제1항에 있어서, 상기 단일 투여 제형은 화합물 I을 10 mg 내지 150 mg 함유하는 것인 조성물.
- 제1항에 있어서, 상기 단일 투여 제형은 화합물 I을 10 mg 내지 100 mg 함유하는 것인 조성물.
- 제1항에 있어서, 상기 단일 투여 제형은 화합물 I을 10 mg 함유하는 것인 조성물.
- 제1항에 있어서, 상기 단일 투여 제형은 화합물 I을 12.5 mg 함유하는 것인 조성물.
- 제1항에 있어서, 상기 단일 투여 제형은 화합물 I을 20 mg 함유하는 것인 조성물.
- 제1항에 있어서, 상기 단일 투여 제형은 화합물 I을 25 mg 함유하는 것인 조성물.
- 제1항에 있어서, 상기 단일 투여 제형은 화합물 I을 50 mg 함유하는 것인 조성물.
- 제1항에 있어서, 상기 단일 투여 제형은 화합물 I을 75 mg 함유하는 것인 조성물.
- 제1항에 있어서, 상기 단일 투여 제형은 화합물 I을 100 mg 함유하는 것인 조성물.
- 제1항에 있어서, 상기 단일 투여 제형은 화합물 I 이외의 다른 항당뇨 화합물을 더 함유하는 것인 조성물.
- 제12 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 인슐린 신호 전달 경로 조절제, 조절이 곤란한 간 글루코오스 생산에 영향을 미치는 화합물, 인슐린 감수성 증강제 및 인슐린 분비 증강제로 이루어진 군으로부터 선택되는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 단백질 티로신 포스파타아제 억제제, 글루타민-프락토오스-6-포스페이트 아미도 전이 효소 억제제, 글루코오스-6-포스파타아제 억제제, 프락토오스-1,6-비스포스파타아제 억제제, 글리코겐 인산화 효소 억제제, 글루카곤 수용체 길항제, 포스포엔올피루브산염 카르복시키나아제 억제제, 피루브산염 탈수소 효소 키나아제 억제제, 알파-글루코시다아제 억제제, 위액 배출 억제제, 글루코키나아제 활성제, GLP-1 수용체 작용제, GLP-2 수용체 작용제, UCP 조절제, RXR 조절제, GSK-3 억제제, PPAR 조절제, 인슐린 및 α2-아드레날린 길항제로 이루어진 군으로부터 선택되는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 GSK-3 억제제, 레티노이드 X 수용체 작용제, 베타-3 AR 작용제, UCP 조절제, 항당뇨 티아졸리딘디온, 비(非)-글라타존 타입 PPAR 감마 작용제, 이중 PPAR 감마/PPAR 알파 작용제, 항당뇨 바나듐 함유 화합물 및 비구아니드로 이루어진 군으로부터 선택되는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 (S)-((3,4-디하이드로-2-(페닐-메틸)-2H-1-벤조피란-6-일)메틸-티아졸리딘-2,4-디온, 5-{[4-(3-(5-메틸-2-페닐-4-옥사졸릴)-1-옥소-프로필)-페닐]-메틸}-티아졸리딘-2,4-디온, 5-{[4-(1-메틸-사이클로헥실)메톡시)-페닐]메틸]-티아졸리딘-2,4-디온, 5-{[4-(2-(1-인돌릴)에톡시)페닐]메틸}-티아졸리딘-2,4-디온, 5-{4-[2-(5-메틸-2-페닐-4-옥사졸리)-에톡시)]벤질}-티아졸리딘-2,4-디온, 5-(2-나프틸술포닐)-티아졸리딘-2,4-디온, 비스{4-[(2,4-디옥소-5-티아졸리디닐)-메틸]페닐}메탄, 5-{4-[2-(5-메틸-2-페닐-4-옥사졸릴)-2-하이드록시에톡시]-벤질}- -티아졸리딘-2,4-디온, 5-[4-(1-페닐-1-사이클로프로판카르보닐아미노)-벤질]-티아졸리딘-2,4-디온, 5-{[4-(2-(2,3-디하이드로인돌-1-일)에톡시)페닐메틸)-티아졸리딘-2,4-디온, 5-[3-(4-클로로-페닐])-2-- 프로피닐]-5-페닐술포닐)티아졸리딘-2,4-디온, 5-[3-(4-클로로페닐])-- 2-프로피닐]-5-(4-플루오로페닐-술포닐)티아졸리딘-2,4-디온,5-{[4-(2-(메틸-2-피리디닐-아미노)-에톡시)페닐]메틸}-티아졸리딘-2,4-디온, 5-{[4-(2-(5-에틸-2-피리딜)에톡시)페닐]-메틸}-티아졸리딘-2,4-디온, 5-([2-(2-나프틸)-벤즈옥사졸-5-일]-메틸}티아졸리딘-2,4-디온 및 5-(2,4-디옥소티아졸리딘-5-일메틸)-2-메톡시-N-(4-트리플루오로메틸-벤질)벤즈아미드 및 이들의 약학적으로 허용 가능한 염으로 이루어진 군으로부터 선택되는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 메트포민 및 이의 약학적으로 허용 가능한 염을 함유하는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 술포닐우레아계 당뇨 치료제를 함유하는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 글리스옥세피드, 글리부리드, 글리벤클라미드, 아세토헥사미드, 클로로프로파미드, 글리보르누리드, 톨부타미드, 톨아자미드, 글리피지드, 카르부타미드, 글리퀴돈, 글리헥사미드, 펜부타미드, 톨클라미드, 글리메피리드 및 글리클라지드 및 이들의 약학적으로 허용 가능한 염으로 이루어진 군으로부터 선택되는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 인크레틴 호르몬 또는 이들의 모방체, 베타-세포 이미다졸린 수용체 길항제 및 단기 작용 인슐린 분비 촉진제로 이루어진 군으로부터 선택되는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 인슐린을 함유하는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 1종 이상의 GLP-1 작용제를 함유하는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 1종 이상의 GLP-2 작용제를 함유하는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 익스텐다티드 (extendatide)를 함유하는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 레파글리니드, 미티글리니드, 나테글리니드 및 이들의 약학적으로 허용 가능한 염으로 이루어진 군으로부터 선택되는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 1종 이상의 알파-글루코시다아제 억제제를 함유하는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 아카르보오스, 보글리보오스, 미글리톨 및 이들의 약학적으로 허용 가능한 염으로 이루어진 군으로부터 선택되는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 로시글리타존 또는 이의 약학적으로 허용 가능한 염을 함유하는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 피오글리타존 또는 이의 약학적으로 허용 가능한 염을 함유하는 것인 조성물.
- 제12항 또는 제13항에 있어서, 상기 1종 이상의 항당뇨 화합물은 메트포민 및 피오글리타존 (이들의 약학적으로 허용가능한 염을 포함한다)을 함유하는 것인 조성물.
- 제30항에 있어서, 피오글리타존은 피오글리타존 HCl 염을 포함하는 것인 조성물.
- 제31항에 있어서, 피오글리타존은 피오글리타존 HCl 염을 포함하는 것인 조성물.
- 제1항 내지 제13항 중 어느 하나의 항에 있어서, 상기 단일 투여 제형은 경구, 비경구, 복막내, 정맥내, 동맥내, 경피, 설하, 근육내, 직장, 구강, 비강내, 흡입, 질내, 안구내, 국소 전달, 피하, 지방내, 관절내 및 경막내로 이루어진 군으로부터 선택되는 경로에 의하여 투여되거나, 약물전달 매개체로서 리포좀을 이용하여 투여되는 것인 조성물.
- 제1항 내지 제13항 중 어느 하나의 항에 있어서, 상기 단일 투여 제형은 경구 투여되는 것인 조성물.
- 제1항 내지 제13항 중 어느 하나의 항에 있어서, 상기 단일 투여 제형은 경구 투여용의 고체 제형인 것인 조성물.
- 제1항 내지 제13항 중 어느 하나의 항에 있어서, 상기 단일 투여 제형은 경구 투여용으로 적합한 정제 또는 캡슐인 것인 조성물.
- 제1항 내지 제13항 중 어느 하나의 항에 있어서, 상기 단일 투여 제형은 경구 투여용으로 적합한 확장형 방출 (extended release) 제형인 것인 조성물.
- 제1항 내지 제13항 중 어느 하나의 항에 있어서, 화합물 I은 조성물 중에 유리 염기로서 존재하는 것인 조성물.
- 제1항 내지 제13항 중 어느 하나의 항에 있어서, 화합물 I은 조성물 중에 약학적으로 허용가능한 염으로서 존재하는 것인 조성물.
- 제1항 내지 제13항 중 어느 하나의 항에 있어서, 화합물 I은 조성물 중에 벤조에이트염으로서 존재하는 것인 조성물.
- 제1항 내지 제13항 중 어느 하나의 항에 있어서, 화합물 I은 조성물 중에 톨루엔술포네이트염으로서 존재하는 것인 조성물.
- 제1항 내지 제13항 중 어느 하나의 항에 있어서, 화합물 I은 조성물 중에 염산염으로서 존재하는 것인 조성물.
- 제1항 내지 제13항 중 어느 하나의 항에 따른 약학 조성물의 다중 투여량을 함유하고,약학 조성물이 투여되는 질병 상태, 약학 조성물의 저장 정보, 투약 정보 및 약학 조성물을 투여하는 방법에 관한 지시를 나타내는 것으로 이루어진 군으로부터 선택되는 1종 이상의 정보 형태를 포함하는 지시서를 포함하는 것인 키트.
- 제1항 내지 제13항 중 어느 하나의 항에 따른 약학 조성물의 다중 투여량과 포장 재료를 포함하는 것인 제조 물품.
- 제45항에 있어서, 포장 재료는 약학 조성물의 다중 투여량을 수납하기 위한 용기를 포함하는 것인 제조 물품.
- 제46항에 있어서, 용기는 화합물이 투여되는 질병 상태, 저장 정보, 투약 정보 및/또는 조성물을 투여하는 방법에 관한 지시로 이루어진 군 중 1종 이상의 것을 나타내는 라벨을 포함하는 것인 제조 물품.
- 다음 화학식을 갖는 화합물 I 및 화합물 I 이외의 다른 항당뇨 화합물을 1종 이상 함유하여 이루어지는, DPP-IV에 의하여 매개되는 증상을 치료하기 위한 단일 투여 제형의 약학 조성물로서, 상기 DPP-IV에 의하여 매개되는 증상은 당뇨병 디스리피데미아 (dislipidemia), 부전 글루코오스 내성 (IGT), 부전 공복 혈장 글루코오스 (IFG), 대사 산증, 케톤증, 식욕 조절, 비만증, 당뇨병 신경병증, 당뇨병 망막병증, 신장병, 고중성 지방혈증, 고콜레스테롤혈증, 저HDL혈증, 식후 고지질혈증, 동맥 경화증, 고혈압, 심근 경색증, 협심증, 뇌 경색증, 뇌졸중 및 대사 증후군으로 이루어진 군으로부터 선택되는 것인 약학 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71755805P | 2005-09-14 | 2005-09-14 | |
US60/717,558 | 2005-09-14 | ||
US74727306P | 2006-05-15 | 2006-05-15 | |
US60/747,273 | 2006-05-15 | ||
PCT/US2006/035708 WO2007033266A2 (en) | 2005-09-14 | 2006-09-13 | Dipeptidyl peptidase inhibitors for treating diabetis |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080055874A KR20080055874A (ko) | 2008-06-19 |
KR101352588B1 true KR101352588B1 (ko) | 2014-01-17 |
Family
ID=37460178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087007906A KR101352588B1 (ko) | 2005-09-14 | 2006-09-13 | 당뇨병 치료용 디펩티딜 펩티다아제 억제제 |
Country Status (31)
Country | Link |
---|---|
US (5) | US20070060528A1 (ko) |
EP (1) | EP1931350B2 (ko) |
JP (2) | JP5190366B2 (ko) |
KR (1) | KR101352588B1 (ko) |
CN (5) | CN102908350B (ko) |
AR (1) | AR059027A1 (ko) |
AU (1) | AU2006290908C1 (ko) |
BR (1) | BRPI0616077B8 (ko) |
CA (1) | CA2622608C (ko) |
CR (1) | CR9875A (ko) |
CY (3) | CY1114925T1 (ko) |
DK (1) | DK1931350T4 (ko) |
EA (1) | EA015735B1 (ko) |
ES (1) | ES2445180T5 (ko) |
GE (1) | GEP20135791B (ko) |
HK (1) | HK1118231A1 (ko) |
HR (1) | HRP20140091T4 (ko) |
HU (2) | HUS1400008I1 (ko) |
IL (1) | IL190133A (ko) |
LU (2) | LU92375I2 (ko) |
MA (1) | MA29799B1 (ko) |
MY (1) | MY159522A (ko) |
NO (3) | NO342682B1 (ko) |
NZ (1) | NZ566797A (ko) |
PE (1) | PE20070458A1 (ko) |
PL (1) | PL1931350T5 (ko) |
PT (1) | PT1931350E (ko) |
RS (1) | RS53155B2 (ko) |
SI (1) | SI1931350T2 (ko) |
TW (1) | TWI421075B (ko) |
WO (1) | WO2007033266A2 (ko) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
EP1506967B1 (en) | 2003-08-13 | 2007-11-21 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005030751A2 (en) * | 2003-09-08 | 2005-04-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2007505121A (ja) * | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
CN102134229B (zh) | 2004-03-15 | 2020-08-04 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
US7931661B2 (en) * | 2004-06-14 | 2011-04-26 | Usgi Medical, Inc. | Apparatus and methods for performing transluminal gastrointestinal procedures |
EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN101282994B (zh) | 2005-07-22 | 2013-09-18 | Y's治疗有限公司 | 抗cd26抗体及其使用方法 |
EA015169B1 (ru) | 2005-09-14 | 2011-06-30 | Такеда Фармасьютикал Компани Лимитед | Применение ингибиторов дипептидилпептидазы |
PT1931350E (pt) * | 2005-09-14 | 2014-02-12 | Takeda Pharmaceutical | Administração de inibidores de dipeptidil peptidase |
CN102675221A (zh) * | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
JP2009531456A (ja) * | 2006-03-28 | 2009-09-03 | 武田薬品工業株式会社 | (r)−3−アミノピペリジン二塩酸塩の調製 |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP2540725A1 (de) | 2006-05-04 | 2013-01-02 | Boehringer Ingelheim International GmbH | Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin |
GEP20125701B (en) * | 2006-09-13 | 2012-12-10 | Takeda Pharmaceuticals Co | Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
WO2008093878A1 (en) * | 2007-02-01 | 2008-08-07 | Takeda Pharmaceutical Company Limited | Tablet preparation without causing a tableting trouble |
MY147596A (en) | 2007-02-01 | 2012-12-31 | Takeda Pharmaceutical | Solid preparation comprising alogliptin and pioglitazone |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
WO2009011451A1 (en) | 2007-07-19 | 2009-01-22 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and metformin hydrochloride |
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
WO2009128360A1 (ja) * | 2008-04-18 | 2009-10-22 | 大日本住友製薬株式会社 | 糖尿病治療剤 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
PE20110297A1 (es) | 2008-08-15 | 2011-05-26 | Boehringer Ingelheim Int | Inhibidores de dpp-4 para la cicatrizacion de heridas |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
WO2010074271A1 (ja) * | 2008-12-26 | 2010-07-01 | 武田薬品工業株式会社 | 糖尿病治療剤 |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
TWI466672B (zh) | 2009-01-29 | 2015-01-01 | Boehringer Ingelheim Int | 小兒科病人糖尿病之治療 |
NZ594487A (en) | 2009-02-13 | 2013-11-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
CA2752437C (en) * | 2009-02-13 | 2017-07-11 | Boehringer Ingelheim International Gmbh | Antidiabetic medications |
NZ599298A (en) | 2009-11-27 | 2014-11-28 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
JP6034781B2 (ja) | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 併用療法 |
EP3725325B1 (en) | 2010-06-24 | 2023-05-31 | Boehringer Ingelheim International GmbH | Diabetes therapy |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
EP2760853A4 (en) * | 2011-09-26 | 2015-10-28 | Hetero Research Foundation | NEW SALTS OF ALOGLIPTIN |
EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EP2767549A1 (en) * | 2013-02-19 | 2014-08-20 | Adienne S.A. | Anti-CD26 antibodies and uses thereof |
US11242399B2 (en) | 2013-02-19 | 2022-02-08 | Adienne S.A. | Anti-CD26 antibodies |
CN103610661B (zh) * | 2013-11-22 | 2017-09-12 | 威海迪素制药有限公司 | 一种组合物 |
TWI677505B (zh) * | 2014-08-18 | 2019-11-21 | 瑞士商艾迪安納股份有限公司 | 抗cd26抗體及其用途 |
WO2017029609A1 (en) * | 2015-08-20 | 2017-02-23 | Torrent Pharmaceuticals Limited | Pharmaceutical composition of alogliptin and metformin |
CN109071490B (zh) * | 2016-04-28 | 2021-04-06 | 默克专利股份公司 | 哌啶基衍生物 |
CA3022202A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
CN107573321A (zh) * | 2017-09-04 | 2018-01-12 | 东南大学 | 4位取代的苯甲酸与阿格列汀形成的盐晶及制备方法 |
JP7413172B2 (ja) | 2020-07-15 | 2024-01-15 | 株式会社東芝 | 通信解析装置およびプログラム |
CN114057685A (zh) * | 2020-07-31 | 2022-02-18 | 西安新通药物研究有限公司 | 一种高收率苯甲酸阿格列汀的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005016911A1 (en) | 2003-08-13 | 2005-02-24 | Takeda Pharmaceutical Company Limited | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
Family Cites Families (169)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3960949A (en) * | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
US4062950A (en) | 1973-09-22 | 1977-12-13 | Bayer Aktiengesellschaft | Amino sugar derivatives |
US4494978A (en) * | 1976-12-30 | 1985-01-22 | Chevron Research Company | Herbicidal N-(N'-hydrocarbyloxycarbamylalkyl)-2,6-dialkyl-alpha-haloacetanilides |
DE3347565A1 (de) | 1983-12-30 | 1985-07-11 | Thomae Gmbh Dr K | Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
JPS6354321A (ja) | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
DE3543999A1 (de) | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
US4935493A (en) * | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
US4981784A (en) | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
CA2067216A1 (en) | 1989-10-25 | 1991-04-26 | Cary Alan Weinberger | Receptor infection assay |
CA2073856C (en) | 1990-01-24 | 2002-12-03 | Douglas I. Buckley | Glp-1 analogs useful for diabetes treatment |
DK0552202T3 (da) | 1990-09-21 | 1996-06-03 | Salk Inst For Biological Studi | Fremgangsmåder medieret af det protoonkogene proteinkompleks AP-1 |
US5387512A (en) * | 1991-06-07 | 1995-02-07 | Merck & Co. Inc. | Preparation of 3-[z-benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2-(1H)-pyridinone by biotransformation |
DK0526171T3 (da) | 1991-07-30 | 1997-08-25 | Ajinomoto Kk | Krystaller af N-(trans-4-isopropylcyclohexylcarbonyl)-Dphenylalanin og fremgangsmåder til fremstilling deraf |
US5866563A (en) | 1991-09-30 | 1999-02-02 | The University Of British Columbia | Vanadium compositions |
WO1993011235A1 (en) | 1991-12-06 | 1993-06-10 | The Salk Institute For Biological Studies | Multimeric forms of members of the steroid/thyroid superfamily of receptors |
DE69334150T2 (de) | 1992-05-14 | 2008-03-13 | Baylor College Of Medicine, Houston | Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie |
IL106998A0 (en) * | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
CA2160135A1 (en) | 1993-04-07 | 1994-10-13 | Donald P. Mcdonnell | Method for screening for receptor agonists |
US5506102A (en) | 1993-10-28 | 1996-04-09 | Ligand Pharmaceuticals Incorporated | Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription |
IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
WO1995018380A1 (en) | 1993-12-30 | 1995-07-06 | The Salk Institute For Biological Studies | Novel uses for gal4-receptor constructs |
US5705515A (en) | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
DE4416433A1 (de) | 1994-05-10 | 1995-11-16 | Hoechst Ag | Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Verwendung der Verbindungen zur Behandlung von Krankheiten |
US5601986A (en) * | 1994-07-14 | 1997-02-11 | Amgen Inc. | Assays and devices for the detection of extrahepatic biliary atresia |
US5488510A (en) | 1994-07-26 | 1996-01-30 | Lemay; Edward J. | Enhanced depth perception viewing device for television |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5614379A (en) * | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
DE69522718T2 (de) | 1995-06-06 | 2002-02-07 | Pfizer | Substituierte n-(indol-2-carbonyl)-amide und derivate als glycogen phosphorylase inhibitoren |
EP0832065B1 (en) | 1995-06-06 | 2001-10-10 | Pfizer Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
EP0862562B1 (en) | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
JPH11514651A (ja) | 1995-10-31 | 1999-12-14 | メルク エンド カンパニー インコーポレーテッド | 置換ピリジルピロール、前記化合物を含む組成物及び使用方法 |
WO1997031901A1 (en) | 1996-02-29 | 1997-09-04 | Mikael Bols | Hydroxyhexahydropyridazines |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US20020006899A1 (en) * | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
EP1019043A4 (en) | 1996-05-07 | 2003-07-30 | Univ Pennsylvania | GLYCOGENE SYNTHETASE KINASE-3 INHIBITORS AND METHODS OF IDENTIFYING AND USING THOSE INHIBITORS |
WO1997046556A1 (en) | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
US5885997A (en) * | 1996-07-01 | 1999-03-23 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
ATE215369T1 (de) | 1996-09-05 | 2002-04-15 | Lilly Co Eli | Carbazolanaloge als selektive beta3-adrenergische agonisten |
US5776954A (en) | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
FR2755439B1 (fr) | 1996-11-05 | 1998-12-24 | Virbac Sa | Derives aryloxypropanolamines, leur procede de preparation et leurs applications |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
AU730295B2 (en) | 1996-11-20 | 2001-03-01 | Merck & Co., Inc. | Triaryl substituted imidazoles as glucagon antagonists |
US5880139A (en) | 1996-11-20 | 1999-03-09 | Merck & Co., Inc. | Triaryl substituted imidazoles as glucagon antagonists |
AU726311B2 (en) | 1996-11-20 | 2000-11-02 | Merck & Co., Inc. | Triaryl substituted imidazoles and methods of use |
CA2271963A1 (en) | 1996-11-20 | 1998-05-28 | Linda L. Chang | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
US5952322A (en) | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
IL131130A0 (en) | 1997-01-28 | 2001-01-28 | Merck & Co Inc | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity |
US20030060434A1 (en) * | 1997-02-18 | 2003-03-27 | Loretta Nielsen | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
DK0970095T3 (da) | 1997-03-07 | 2004-03-08 | Metabasis Therapeutics Inc | Hidtil ukendte benzimidazolinhibitorer for fructose-1,6-bisphosphase |
WO1998039342A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
JP2001514631A (ja) | 1997-03-07 | 2001-09-11 | ノボ ノルディスク アクティーゼルスカブ | 4,5,6,7−テトラヒドロ−チエノ[3,2−c]ピリジン誘導体類、それらの製造方法及び使用 |
BR9810378A (pt) | 1997-07-01 | 2000-08-29 | Novo Nordisk As | Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero |
US6235493B1 (en) * | 1997-08-06 | 2001-05-22 | The Regents Of The University Of California | Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue |
US6169087B1 (en) | 1997-09-23 | 2001-01-02 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPases) |
US6485955B1 (en) * | 1997-10-06 | 2002-11-26 | The Trustees Of Tufts University | Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease |
US6342611B1 (en) * | 1997-10-10 | 2002-01-29 | Cytovia, Inc. | Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof |
WO1999025719A1 (fr) * | 1997-11-18 | 1999-05-27 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Substance physiologiquement active, la sulphostine, procede de fabrication et utilisation |
FR2771004B1 (fr) * | 1997-11-19 | 2000-02-18 | Inst Curie | Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse |
UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
WO1999029672A1 (en) | 1997-12-05 | 1999-06-17 | Eli Lilly And Company | SELECTIVE β3 ADRENERGIC AGONISTS |
US6380357B2 (en) * | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
JP3979622B2 (ja) * | 1997-12-16 | 2007-09-19 | ノボザイムス アクティーゼルスカブ | アミノペプチダーゼ活性を有するポリペプチド及びこれをコードする核酸 |
AU2610299A (en) | 1998-02-05 | 1999-08-23 | Novo Nordisk A/S | Hydrazone derivatives |
US5998463A (en) | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
US20020061839A1 (en) * | 1998-03-09 | 2002-05-23 | Scharpe Simon Lodewijk | Serine peptidase modulators |
AU2713799A (en) | 1998-03-12 | 1999-09-27 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
HUP0102612A2 (hu) | 1998-03-12 | 2001-11-28 | Novo Nordisk A/S | Fehérje-tirozinfoszfatázokat moduláló vegyületek és ezeket tartalmazó gyógyászati készítmények |
AU2713699A (en) | 1998-03-12 | 1999-09-27 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
WO1999046267A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
JP2002506073A (ja) | 1998-03-12 | 2002-02-26 | ノボ ノルディスク アクティーゼルスカブ | プロテイン・チロシン・ホスファターゼ(PTPases)のモジュレーター |
AU3087099A (en) | 1998-03-16 | 1999-10-11 | Ontogen Corporation | Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase) |
ATE286032T1 (de) | 1998-04-23 | 2005-01-15 | Reddys Lab Ltd Dr | Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen |
US6001867A (en) | 1998-05-12 | 1999-12-14 | American Home Products Corporation | 1-aryl-dibenzothiophenes |
US6057316A (en) | 1998-05-12 | 2000-05-02 | American Home Products Corporation | 4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes |
EP1077967B1 (en) | 1998-05-12 | 2002-12-04 | Wyeth | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
CN1308625A (zh) | 1998-05-12 | 2001-08-15 | 美国家用产品公司 | 萘并[2,3-b]杂芳-4-基衍生物 |
ATE231512T1 (de) * | 1998-06-05 | 2003-02-15 | Point Therapeutics Inc | Cyclische boroprolinverbindungen |
DE19828113A1 (de) * | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19834591A1 (de) * | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
EP0978279A1 (en) | 1998-08-07 | 2000-02-09 | Pfizer Products Inc. | Inhibitors of human glycogen phosphorylase |
WO2000014090A1 (en) | 1998-09-02 | 2000-03-16 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno[2,3-c]pyridine derivatives |
PT1112275E (pt) | 1998-09-09 | 2003-12-31 | Metabasis Therapeutics Inc | Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase |
EP1119548B1 (en) | 1998-10-08 | 2004-12-08 | SmithKline Beecham plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione as glycogen synthase kinase-3 inhibitor (gsk-3) |
GB9905416D0 (en) | 1999-03-09 | 1999-05-05 | Allelix Biopharma | Small molecules having GLP-2 like activity |
GB9906715D0 (en) * | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for promoting growth |
US6548529B1 (en) * | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
SI1180121T1 (en) * | 1999-05-17 | 2004-04-30 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
DE19926233C1 (de) * | 1999-06-10 | 2000-10-19 | Probiodrug Ges Fuer Arzneim | Verfahren zur Herstellung von Thiazolidin |
GB2351081A (en) | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Pharmaceutically active imidazoline compounds and analogues thereof |
US6172081B1 (en) * | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
US6528486B1 (en) * | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
US6030837A (en) | 1999-08-03 | 2000-02-29 | Isis Pharmaceuticals Inc. | Antisense inhibition of PEPCK-mitochondrial expression |
DE19940130A1 (de) * | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US6251391B1 (en) * | 1999-10-01 | 2001-06-26 | Klaire Laboratories, Inc. | Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons |
GB9928330D0 (en) * | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
WO2001041779A2 (en) * | 1999-12-08 | 2001-06-14 | 1149336 Ontario Inc. | Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment |
GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
DE60102899T2 (de) * | 2000-01-27 | 2005-03-31 | Eli Lilly And Co., Indianapolis | Verfahren zur lösung von glucagon-ähnlichen peptid-1 (glp-1) verbindungen |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US6555519B2 (en) * | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
ATE419036T1 (de) * | 2000-03-31 | 2009-01-15 | Prosidion Ltd | Verbesserung der aktivität der inselzellen bei diabetes mellitus und dessen prävention |
US6573096B1 (en) * | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
US6545170B2 (en) * | 2000-04-13 | 2003-04-08 | Pharmacia Corporation | 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
GB0010188D0 (en) * | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
US6783757B2 (en) * | 2000-06-01 | 2004-08-31 | Kirkman Group, Inc. | Composition and method for increasing exorphin catabolism to treat autism |
AU6895801A (en) * | 2000-07-04 | 2002-01-14 | Novo Nordisk As | Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv |
US20020037829A1 (en) * | 2000-08-23 | 2002-03-28 | Aronson Peter S. | Use of DPPIV inhibitors as diuretic and anti-hypertensive agents |
EP1324995A2 (en) * | 2000-09-27 | 2003-07-09 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
TWI290919B (en) * | 2000-10-06 | 2007-12-11 | Tanabe Seiyaku Co | Nitrogen-containing five-membered ring compound, a pharmacologically permissible salt thereof and the method for producing the same |
AUPR107800A0 (en) * | 2000-10-27 | 2000-11-23 | University Of Sydney, The | Peptide and nucleic acid molecule ii |
JP2004518718A (ja) * | 2000-10-30 | 2004-06-24 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 抗糖尿病薬および抗痙攣薬を含んで成る併用療法 |
TWI243162B (en) * | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
US20030055052A1 (en) * | 2000-11-10 | 2003-03-20 | Stefan Peters | FAP-activated anti-tumor compounds |
JP2004536023A (ja) * | 2000-11-20 | 2004-12-02 | ブリストル−マイヤーズ スクイブ カンパニー | aP2インヒビターとしてのピリドン誘導体 |
BR0206831A (pt) * | 2001-02-02 | 2004-07-06 | Takeda Chemical Industries Ltd | Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto |
DK1953162T3 (da) * | 2001-02-24 | 2012-09-10 | Boehringer Ingelheim Pharma | Xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel. |
US6337069B1 (en) * | 2001-02-28 | 2002-01-08 | B.M.R.A. Corporation B.V. | Method of treating rhinitis or sinusitis by intranasally administering a peptidase |
KR100863089B1 (ko) * | 2001-03-19 | 2008-10-13 | 노파르티스 아게 | 지사제 및 에포틸론 또는 에포틸론 유도체를 포함하는혼합물 |
FR2822826B1 (fr) * | 2001-03-28 | 2003-05-09 | Servier Lab | Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6890905B2 (en) * | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
PE20021080A1 (es) * | 2001-04-12 | 2003-02-12 | Boehringer Ingelheim Int | Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer |
FR2824825B1 (fr) * | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US7105556B2 (en) * | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
US6794379B2 (en) * | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
US7368421B2 (en) * | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
US6844316B2 (en) * | 2001-09-06 | 2005-01-18 | Probiodrug Ag | Inhibitors of dipeptidyl peptidase I |
US6673829B2 (en) * | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
RS26604A (en) * | 2001-10-01 | 2006-12-15 | Bristol Myers Squibb Company | Spiro-hydantoin compounds useful as anti-inflamatory agents |
GB0125445D0 (en) * | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
US6861440B2 (en) * | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
US6673815B2 (en) * | 2001-11-06 | 2004-01-06 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US20030125304A1 (en) * | 2001-11-09 | 2003-07-03 | Hans-Ulrich Demuth | Substituted amino ketone compounds |
US20030089935A1 (en) * | 2001-11-13 | 2003-05-15 | Macronix International Co., Ltd. | Non-volatile semiconductor memory device with multi-layer gate insulating structure |
US6727261B2 (en) * | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
ES2345096T3 (es) * | 2002-02-13 | 2010-09-15 | F. Hoffmann-La Roche Ag | Nuevos derivados de piridina y pirimidina. |
TW200307667A (en) * | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
AU2003243316A1 (en) | 2002-05-24 | 2003-12-12 | Nps Allelix Corp. | Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides |
US6710040B1 (en) * | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
WO2003101449A2 (en) * | 2002-06-04 | 2003-12-11 | Pfizer Products Inc. | Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof |
US20040009972A1 (en) * | 2002-06-17 | 2004-01-15 | Ding Charles Z. | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase |
US20040054171A1 (en) * | 2002-07-04 | 2004-03-18 | Jensen Anette Frost | Polymorphic forms of a 4H-thieno[3,2-E]-1,2,4-thiadiazine 1,1-dioxide derivative |
US7407955B2 (en) * | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
EP3424926A1 (de) † | 2002-08-21 | 2019-01-09 | Boehringer Ingelheim Pharma GmbH & Co. KG | 8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als arzneimittel |
US20040058876A1 (en) * | 2002-09-18 | 2004-03-25 | Torsten Hoffmann | Secondary binding site of dipeptidyl peptidase IV (DP IV) |
US6869966B2 (en) * | 2002-09-30 | 2005-03-22 | Banyu Pharmaceutical Co., Ltd. | N-substituted-2-oxodihydropyridine derivatives |
US7109192B2 (en) * | 2002-12-03 | 2006-09-19 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions |
US20050014732A1 (en) * | 2003-03-14 | 2005-01-20 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-diabetic agent |
US7687625B2 (en) † | 2003-03-25 | 2010-03-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN101837127A (zh) * | 2003-05-05 | 2010-09-22 | 前体生物药物股份公司 | 谷氨酰胺酰基和谷氨酸环化酶效应物的应用 |
US7566707B2 (en) * | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
JO2625B1 (en) * | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
US6995183B2 (en) * | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
WO2005019168A2 (en) * | 2003-08-20 | 2005-03-03 | Pfizer Products Inc. | Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors |
WO2005030751A2 (en) † | 2003-09-08 | 2005-04-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2007505121A (ja) † | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
CN102134229B (zh) * | 2004-03-15 | 2020-08-04 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
AU2005299808B2 (en) * | 2004-10-25 | 2009-08-20 | Novartis Ag | Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin |
PT1931350E (pt) * | 2005-09-14 | 2014-02-12 | Takeda Pharmaceutical | Administração de inibidores de dipeptidil peptidase |
-
2006
- 2006-09-13 PT PT68035237T patent/PT1931350E/pt unknown
- 2006-09-13 US US11/531,495 patent/US20070060528A1/en not_active Abandoned
- 2006-09-13 GE GEAP200610608A patent/GEP20135791B/en unknown
- 2006-09-13 WO PCT/US2006/035708 patent/WO2007033266A2/en active Application Filing
- 2006-09-13 CA CA2622608A patent/CA2622608C/en active Active
- 2006-09-13 KR KR1020087007906A patent/KR101352588B1/ko active IP Right Review Request
- 2006-09-13 SI SI200631737T patent/SI1931350T2/sl unknown
- 2006-09-13 JP JP2008531294A patent/JP5190366B2/ja active Active
- 2006-09-13 EP EP06803523.7A patent/EP1931350B2/en active Active
- 2006-09-13 PL PL06803523T patent/PL1931350T5/pl unknown
- 2006-09-13 BR BRPI0616077A patent/BRPI0616077B8/pt active IP Right Grant
- 2006-09-13 RS RS20140046A patent/RS53155B2/sr unknown
- 2006-09-13 EA EA200800727A patent/EA015735B1/ru active Protection Beyond IP Right Term
- 2006-09-13 CN CN201210398616.XA patent/CN102908350B/zh active Active
- 2006-09-13 MY MYPI20080653A patent/MY159522A/en unknown
- 2006-09-13 PE PE2006001113A patent/PE20070458A1/es active IP Right Grant
- 2006-09-13 HR HRP20140091TT patent/HRP20140091T4/hr unknown
- 2006-09-13 CN CN201210332314.2A patent/CN102940638B/zh active Active
- 2006-09-13 CN CN2006800424178A patent/CN101309689B/zh active Active
- 2006-09-13 DK DK06803523.7T patent/DK1931350T4/da active
- 2006-09-13 AU AU2006290908A patent/AU2006290908C1/en active Active
- 2006-09-13 NZ NZ566797A patent/NZ566797A/en unknown
- 2006-09-13 CN CN201210399309.3A patent/CN102908351B/zh active Active
- 2006-09-13 ES ES06803523T patent/ES2445180T5/es active Active
- 2006-09-13 CN CN201210332271.8A patent/CN102935081B/zh active Active
- 2006-09-14 AR ARP060104030A patent/AR059027A1/es not_active Application Discontinuation
- 2006-09-14 TW TW095134082A patent/TWI421075B/zh active
-
2008
- 2008-03-12 IL IL190133A patent/IL190133A/en active IP Right Grant
- 2008-03-19 MA MA30773A patent/MA29799B1/fr unknown
- 2008-03-31 NO NO20081569A patent/NO342682B1/no active Protection Beyond IP Right Term
- 2008-04-09 CR CR9875A patent/CR9875A/es unknown
- 2008-11-12 HK HK08112374.3A patent/HK1118231A1/xx active IP Right Maintenance
-
2011
- 2011-04-05 US US13/080,434 patent/US20110212982A1/en not_active Abandoned
-
2012
- 2012-12-18 JP JP2012276223A patent/JP5567650B2/ja active Active
-
2014
- 2014-02-06 CY CY20141100098T patent/CY1114925T1/el unknown
- 2014-02-12 LU LU92375C patent/LU92375I2/xx unknown
- 2014-02-12 LU LU92376C patent/LU92376I2/xx unknown
- 2014-02-25 CY CY2014011C patent/CY2014011I1/el unknown
- 2014-02-25 CY CY2014012C patent/CY2014012I2/el unknown
- 2014-03-04 HU HUS1400008C patent/HUS1400008I1/hu unknown
- 2014-03-04 HU HUS1400009C patent/HUS1400009I1/hu unknown
- 2014-05-19 US US14/280,942 patent/US20140256757A1/en not_active Abandoned
-
2017
- 2017-09-29 US US15/721,342 patent/US20180140589A1/en not_active Abandoned
-
2018
- 2018-09-04 NO NO2018029C patent/NO2018029I2/no unknown
- 2018-09-04 NO NO2018028C patent/NO2018028I2/no unknown
-
2019
- 2019-02-15 US US16/277,537 patent/US20190314352A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005016911A1 (en) | 2003-08-13 | 2005-02-24 | Takeda Pharmaceutical Company Limited | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101352588B1 (ko) | 당뇨병 치료용 디펩티딜 펩티다아제 억제제 | |
KR101345316B1 (ko) | 당뇨병 치료용 디펩티딜 펩티다아제 억제제 | |
KR102062824B1 (ko) | 2-[6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸]-4-플루오로-벤조니트릴의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
A101 | Application to extend term of patent right by permit | ||
J204 | Request for invalidation trial [patent] | ||
J121 | Written withdrawal of request for trial | ||
J204 | Request for invalidation trial [patent] | ||
J121 | Written withdrawal of request for trial | ||
J501 | Disposition of invalidation of trial | ||
J501 | Disposition of invalidation of trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
FPAY | Annual fee payment |
Payment date: 20161230 Year of fee payment: 4 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2015100002656; TRIAL DECISION FOR INVALIDATION REQUESTED 20150410 Effective date: 20171101 Free format text: TRIAL NUMBER: 2015100002646; TRIAL DECISION FOR INVALIDATION REQUESTED 20150410 Effective date: 20171101 Free format text: TRIAL NUMBER: 2015100002632; TRIAL DECISION FOR INVALIDATION REQUESTED 20150410 Effective date: 20171101 Free format text: TRIAL NUMBER: 2015100002654; TRIAL DECISION FOR INVALIDATION REQUESTED 20150410 Effective date: 20171101 Free format text: TRIAL NUMBER: 2015100002658; TRIAL DECISION FOR INVALIDATION REQUESTED 20150410 Effective date: 20171101 |
|
J121 | Written withdrawal of request for trial | ||
FPAY | Annual fee payment |
Payment date: 20171228 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20191226 Year of fee payment: 7 |